BRAF 测试市场：市场规模（按细分市场）、份额、监管、报销、预测（~2033 年）

黑色素瘤在全球最常见的恶性肿瘤中排名第 19 位，估计年龄标准化发生率为每 10 万人 2.8 至 3.1 例。 各国之间的发病率差异很大，其中澳洲发病率最高（每 10 万人 37 例），中亚和南亚发病率最低（每 10 万人 0.2 例）。 这些模式是由于种族不同的皮肤表型差异以及世界各地阳光照射的差异所造成的。 引起皮肤黑色素瘤的基本环境因素是紫外线。

大肠癌 (CRC) 是男性第三大常见癌症，女性第二常见癌症。 据世界卫生组织 (WHO) 称，2018 年报告了约 180 万新发结直肠癌病例。 肺癌是第二常见的癌症，2018 年报告的肺癌新病例约 200 万例。 吸烟是所有年龄层肺癌的主要危险因素，全世界约 80% 的男性肺癌病例和 45% 的女性肺癌病例可归因于吸烟。

BRAF 基因为製造将特定讯号从细胞外传递到细胞核的蛋白质提供了指导。 该蛋白是 RAF/MAPK 讯号通路的一部分，该通路控制多种重要的细胞功能。 特别是，RAF/MAPK 路径指导细胞发育和分裂（增殖）、细胞发育成特定功能（分化）、细胞运动（迁移）和细胞破裂（凋亡）的步骤。 透过此途径的化学讯号传导是典型产前发育的基础。

BRAF检测包括BRAF免疫组织化学（IHC）、BRAF桑格定序、BRAF核酸扩增检测（NAAT）、BRAF其他检测（BRAF原位杂交（ISH）、质谱阵列检测）。

本报告深入探讨了全球 BRAF 测试市场，包括竞争格局、SWOT 分析、到 2033 年的市场预测、COVID-19 的影响以及区域和国家趋势。Masu。

目录

目前BRAF测试的市场及竞争状况

• 对主要产业趋势的见解
• 2015 年至 2033 年 BRAF 测试按细分市场划分的市场总收入和市场前景
• 有关数量、平均售价和市场价值的详细数据

全球、区域与国家见解

• BRAF测试市场的SWOT分析
• BRAF 测试市场的竞争动态洞察与趋势
• 各国医疗保健系统概览
• 按国家/地区划分的报销政策
• 各国医疗科技的监管状况

Abstract

BRAF Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on BRAF Tests market for the year 2020 and beyond. Melanoma is accounted for as the nineteenth most basic malignant growth around the world, with assessed age-standardized frequency rates of 2.8-3.1 per 100,000. There is significant variety in frequency between nations, with the highest rates seen in Australia (37 for every 100,000) and the least in South-Central Asia (0.2 per 100,000). This pattern is ascribed to varieties in racial skin phenotype, just as contrasts in sun exposure around the globe. The fundamental environmental factor causing cutaneous melanoma is UV radiation.

Colorectal cancer (CRC) is the third most common cancer in men and the second most common cancer in women. Approximately 1.8 million new CRC incident cases were reported in 2018, according to the World Health Organization. Lung cancer is the second most common cancer with approximately 2.0 million new cases of lung cancer reported in 2018. Cigarette smoking is the dominant risk factor associated with lung cancer across all age groups, with approximately 80% of male and 45% of female lung cancer cases worldwide attributed to smoking.

The BRAF gene gives guidelines to making a protein that transmits specific signals from outside the cell to the cell's nucleus. This protein is a piece of a signaling pathway known as the RAF/MAPK pathway, which controls a few significant cell functions. In particular, the RAF/MAPK pathway directs the development and division (proliferation) of cells, the procedure by which cells develop to specific functions (differentiation), cell movement (migration), and the implosion of cells (apoptosis). Chemical signaling through this pathway is basic for typical development before birth.

The BRAF tests include BRAF Immunohistochemistry (IHC), BRAF Sanger sequencing, BRAF Nucleic Acid Amplification Tests (NAATs) and BRAF other Tests (BRAF In Situ Hybridization (ISH), Mass Array Tests).

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed BRAF Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total BRAF Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for BRAF Tests market.
• Competitive dynamics insights and trends provided for BRAF Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: F. Hoffmann-La Roche Ltd, bioMerieux SA, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, Takara Bio Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, Biocartis Group NV, BGI Genomics Co Ltd, and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the BRAF Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on BRAF Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving BRAF Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BRAF Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific BRAF Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable